Avacta Group (LON:AVCT) Stock Price Down 7.4% - What's Next?

Key Points

• Avacta Group Plc shares declined by 7.4% during mid-day trading on Friday, reaching a low of GBX 47 ($0.62) before closing at GBX 47.70 ($0.63).
• The company reported a negative net margin of 114.45% and a negative return on equity of 74.00%, indicating ongoing financial challenges.
• Analysts predict that Avacta Group will post -9.90 earnings per share for the current year, signaling expectations of further losses.

Avacta Group Plc (LON:AVCT - Get Free Report)'s stock price fell 7.4% during mid-day trading on Friday . The company traded as low as GBX 47 ($0.62) and last traded at GBX 47.70 ($0.63). 2,786,073 shares were traded during trading, an increase of 34% from the average session volume of 2,075,455 shares. The stock had previously closed at GBX 51.50 ($0.68).

Avacta Group Stock Performance

The stock's 50-day simple moving average is GBX 35.55 and its 200-day simple moving average is GBX 37.56. The stock has a market cap of £203.25 million, a price-to-earnings ratio of -6.88 and a beta of 1.12. The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53.

Avacta Group (LON:AVCT - Get Free Report) last announced its earnings results on Friday, June 6th. The biotechnology company reported GBX (8.54) (($0.11)) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. Analysts forecast that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).